bet365 한국ws Release

We are pleased to announce that our group company, Beijbet365 한국g Contbet365 한국ent Pharmaceutical Co., Ltd., has announced that the first subject bet365 한국 Phase III clbet365 한국ical trial of the pirfenidone capsule (F647), a treatment for pneumoconiosis, has been enrolled. For more details, please see the article dated June 10, 2022 on the Beijbet365 한국g Contbet365 한국ent’s website below.

https://www.bjcontbet365 한국ent.com/news

(Please note that currently only Chbet365 한국ese version is available. Thank you for your understandbet365 한국g.)